We have to start globally funding increased R&D here before it’s too late. Over time, due to heavy use and natural evolution of bacteria, we have seen a significant increase in resistant strains that defy standard treatment courses. This is coupled with regulatory approval pressures and economic pressures that are reducing the innovation and funding for new antibiotic research. As these two trends converge, a crisis is brewing that we need to address.
Read a related article here: http://n.pr/1KmJoth